Table 1.
Baseline characteristics.
| Characteristic | Number (%)a |
|---|---|
| Age (Years) | |
| Median | 61.5 |
| Range | 45–87 |
| Sex | |
| Male | 11 (92%) |
| Female | 1 (8%) |
| Primary site | |
| Oral cavity | 4 (33%) |
| Oropharynx | 6 (50%) |
| Paranasal sinus | 1 (8%) |
| Unknown primary | 1 (8%) |
| Prior anti-EGFR therapyb | |
| Cetuximab | 5 (42%) |
| Erlotinib | 2 (17%) |
| None | 5 (42%) |
| ECOG performance status | |
| 0 | 5 (42%) |
| 1 | 5 (42%) |
| 2 | 2 (17%) |
| Tobacco use | |
| Current | 3 (25%) |
| Former | 7 (58%) |
| None | 2 (17%) |
| p16 Status | |
| Positive | 6 (50%) |
| Negative | 6 (50%) |
a
Number (percent) unless units otherwise specified.
b
Prior anti-EGFR therapy delivered with concurrent chemoradiotherapy for localized disease.